Sartorius Stedim Biotech stock

DIM · Euronext Paris · EUR

Compare Sartorius Stedim Biotech
€225.20Change from previous close: +0.90%Absolute change: +€2.00

Close · November 16, 2026

Price history

+19.02% over the period

1 year: from €190.05 (November 17, 2025) to €226.20 (November 16, 2026), +19.02%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026€226.20
October 30, 2026€223.40
September 30, 2026€212.80
August 31, 2026€196.00
July 31, 2026€166.70
June 30, 2026€181.60
May 29, 2026€178.10
April 30, 2026€156.70
March 31, 2026€166.20
February 27, 2026€183.10
January 30, 2026€188.30
December 31, 2025€210.00
November 28, 2025€207.30
November 17, 2025€190.05

At a glance

  • The company

    Produce instruments and consumables for biopharmaceutical manufacturing, including bioreactors, cell culture media, purification systems, and lab analytics software

  • Latest results

    Quarter to September 30, 2026 · EPS €1.18 (estimate €1.21)

TickerLandia's take on Sartorius Stedim Biotech

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€150.00
52-wk high€229.80

−2.00% from the 52-week high

Analysts · 13 analysts

Average target€250.00+11.01% vs. price

Buy 12 · Hold 1 · Sell 0 · Buy

TickerLandia Fingerprint: Sartorius Stedim Biotech

Compared with similar companies: very strong momentum.

Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Sartorius Stedim Biotech is pricier than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Sartorius Stedim Biotech's P/E today is 82.9, above the median of its last 10 fiscal years (64.6; between 31.8 and 107.3 from 2016 to 2025). Sartorius Stedim Biotech's P/E (trailing 12 months): 67.0, +60% against the median of a group of 10 similar companies (41.9).

P/E compared with its history

Compared with 10 similar companies

Sartorius Stedim Biotech's metrics compared with similar companies
MetricSartorius Stedim BiotechPosition in the groupBand
P/E (trailing 12 months)67.0High
Forward P/E36.8High
Operating margin19.2%Middle
ROE7.7%Middle
Debt/equity0.53Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Sartorius Stedim Biotech. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€762.1M

Latest quarter · Q3 2026

Net income

€95.5M

Latest quarter · Q3 2026

Quarterly net margin

12.5%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
€21.72B
P/E
67.0
EPS
€3.33
Volume
56.55K
Daily trading
€21.17M
Dividend yield
0.31%
Last ex-dividend on March 31, 2026

How Sartorius Stedim Biotech is changing

All results
  • Revenue grew 9.2% a year on average over the last 5 years

  • Operating margin fell from 30.2% to 18.1%

  • Profits turn into cash: free cash flow equal to 139% of net income

Returns

Sartorius Stedim Biotech returns with dividends

€1,000 invested in Sartorius Stedim Biotech 5 years ago, on November 16, 2021, would be worth €485 today with dividends reinvested: −51.52% in total, −13.48% per year. On price alone it would be €476 (−52.42%).

PeriodSartorius Stedim BiotechCAC 40€1,000 becomes
1 month+5.21%+5.30%€1,052
6 months+44.45%+5.35%€1,445
Year to date+7.71%+2.81%€1,077
1 year+19.52%+3.19%€1,195
3 years+15.14%+16.88%€1,151
5 years−51.52%+17.14%€485
10 years+300.60%+86.14%€4,006

Over the last 6 months it has done better than 77% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. CAC 40: price only. Calculate your investment

The chart in detail

Sartorius Stedim Biotech: technical analysis

Sartorius Stedim Biotech is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 58.9% below its all-time closing high (€548.20, September 10, 2021).

Trend
Upward
RSI (14 sessions)
58
Between 30 and 70
vs 200-session average
+22.39%

Active signals

  • The price is moving in an unusually narrow range compared with the last year.

Support and resistance

Price areas where Sartorius Stedim Biotech has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price€225.20
  3. Support€224.50−0.31%2 touches, last on October 6, 2026
  4. Support€202.70−9.99%3 touches, last on October 2, 2026
  5. Support€184.10−18.25%3 touches, last on September 14, 2026

Volatility and risk

Over the last year it has moved roughly in line with the CAC 40.

Beta (1 year) vs CAC 40
1.03
Volatility (60 sessions, annualised)
30.1%
Largest fall in the last year
−32.06%

Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Sartorius Stedim Biotech: seasonality

Average monthly price change over 27 years

+4.7%Jan+4.7%Feb+0.3%Mar+3.2%Apr+1.9%May+1.7%Jun+3.5%Jul+3.1%Aug−2.1%Sep+0.1%Oct+0.8%Nov+3.2%Dec

Over the last 27 years, the strongest month for Sartorius Stedim Biotech has been January: +4.68% on average, positive in 18 years out of 26. The weakest has been September: −2.07% on average, positive in 10 years out of 27. November, the current month, has been positive in 16 years out of 26 (+0.83% on average).

Show chart data
MonthAverageMedianPositive years
January+4.68%+5.31%18 of 26
February+4.67%+4.93%18 of 27
March+0.34%+0.89%15 of 27
April+3.21%+2.37%17 of 27
May+1.93%+2.62%17 of 27
June+1.70%+1.38%16 of 27
July+3.48%+4.17%17 of 27
August+3.12%+0.58%15 of 27
September−2.07%−2.38%10 of 27
October+0.07%−0.15%13 of 27
November+0.83%+1.49%16 of 26
December+3.22%+2.93%17 of 26

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Sartorius Stedim Biotech and its competitors

Based in Aubagne, France, Sartorius Stedim Biotech S.A. has existed since its incorporation in 1978. The company makes instruments and consumables for the biopharmaceutical industry worldwide, among them cell culture media, bioreactors, separation and purification products, storage and transport systems for biological materials, pipettes, sensors, water purification systems and weighing products. Its customers include drug and vaccine manufacturers, food and chemical producers, and research and development laboratories. A collaboration with Bio Usawa Biotechnology, Ltd. covers antibody development in Africa.

Headquarters
Aubagne, France
Employees
10,483
Founded
1978
Chief executive
Rene Faber
Sartorius Stedim Biotech and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Sartorius Stedim BiotechDIM$24B19.2%67.0+44.45%
Straumann HoldingSTMN$20.69B24.7%47.1+30.05%
SartoriusSRT$19.89B17.8%79.3+37.44%
ColoplastCOLO.B$16.93B25.7%37.2+27.77%
AlconALC$35.8B12.9%57.3+23.24%
Ypsomed HoldingYPSN$6.77B36.2%34.3+44.57%

Same industry or related industries, similar size. Compare Sartorius Stedim Biotech with its competitors · Full profile